問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

蔡禮賢
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

20Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡禮賢

List

22Cases

2025-06-30 - 2032-05-01

Phase II

Active
A phase 2, open-label, multi-population trial evaluating the efficacy and safety of ASP5541 in participants with advanced prostate cancer.

  • Condition/Disease

    * Percentage of mCRPC participants who have not used ARPI and whose PSA has decreased by ≥90% from baseline.* Incidence of no mineral corticosteroid toxicity (defined as no ≥ Grade 1 hypokalemia and no ≥ Grade 2 hypertension).* Percentage of mHSPC participants with PSA ≤ 0.2 ng/mL at 8 months.* DLT, AE, SAE, laboratory test results (including chemistry, hematology, and urinalysis), ECG, vital signs, physical examination, and ECOG performance status score.

  • Test Drug

    "Chengda" Prednisone Tablets 5 mg (Penisol) "Boli" Concentrate Tablets 5 mg (Penisol) Abiraterone acetate ASP5541 (Abiraterone decanoate) Cosyntropin Prednisone Abiraterone Tablets 250 mg Prednisone Tablets Erezhi Film-Coated Tablets 250 mg Lerdan Tablets

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Intravenous infusion solution Intravenous infusion solution Tablets

Participate Sites
5Sites

Recruiting5Sites

2023-03-20 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2023-10-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-03-25 - 2026-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

Terminated1Sites

2024-06-01 - 2028-03-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-12-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2034-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2021-08-15 - 2034-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB